Skip to main content
Log in

Effects of doxorubicin on the canine erythroid and myeloid progenitor cells and bone marrow microenvironment

  • Original Articles
  • Published:
Comparative Haematology International Aims and scope Submit manuscript

Abstract

The antineoplastic drug doxorubicin is known to cause cytopenias. In humans and in dogs treated with doxorubicin, neutropenia is a common haematological toxicity. To determine the mechanism of doxorubicin haematotoxicity in the dog, in vitro bone marrow progenitor and microenvironment assays were done in the presence of doxorubicin. The 50% inhibitory concentration (IC50) of doxorubicin for canine erythroid colony-forming unit (CFU-E) was 0.042 ± 0.01 μM and for canine granulocyte-macrophage colony-forming unit (CFU-GM) it was 0.0084 ± 0.002 μM To determine the effects of doxorubicin on the bone marrow microenvironment, fibroblast colony-forming unit (CFU-F) assays were performed. The 50% inhibitory concentration for canine CFU-F was 0.030 ± 0.01 μM. Morphologically, the CFU-F were made up of predominantly cells (73 ± 8%) with fibroblast-like morphology. Within the colonies as well as between the colonies, there were cells with macrophage (27 ± 8%) morphology. To support the morphological classification of these cells, cytochemical staining was done. The cells with the fibroblast-like morphology were negative for butyrate esterase and those with macrophage morphology were positive, whereas both cell types were positive for acid phosphatase in the presence or absence of tartrate. Our data show that the effects of doxorubicin on in vitro haematopoiesis in the dog are similar to those described in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aghai E, Tokes ZA (1990) Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells. Cancer Chemother Pharmacol 25:295–298

    Google Scholar 

  • Bailey-Wood R, Dallimore CM, Whittaker JA (1984) Effect of adriamycin on CFU-GM at plasma concentrations found following therapeutic infusion. Br J Cancer 50:351–355

    Google Scholar 

  • Benjamin RS, Wiernik PH, Bachur NR (1974) Adriamycin chemotherapy: efficacy, safety, and pharmacology basis of an intermittent single high-dosage schedule. Cancer 33:19–27

    Google Scholar 

  • Blum RH, Carter SK (1974) Adriamycin: a new anthracycline drug with significant clinical activity. Ann Intern Med 80:249–259

    Google Scholar 

  • Bonadonna G, Monfardini S, DeLena M, Fossati-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin. Cancer Res 30:2572–2582

    Google Scholar 

  • Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125

    Google Scholar 

  • Broudy VC, Zucherman KS, Jetmalani S, Fitchen JH, Grover C, Bagby J (1986) Monocytes stimulate fibroblastoid bone marrow stromal cells to produce multilineage hematopoietic growth factors. Blood 68:530–534

    Google Scholar 

  • Busch FW, Schmittele U, Ehninger G (1990) Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil. Blut 60:219–222

    Google Scholar 

  • Carter RF, Harris CK, Withrow SJ, Vali VEO, Susaneck SJ (1987) Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 23:587–596

    Google Scholar 

  • Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P et al. (1980) Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56:289–301

    Google Scholar 

  • Chabner BA, Myers CE (1989) Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. J. B. Lippincott, Philadelphia, PA, pp 349–395

    Google Scholar 

  • Charbord P, Tamayo E, Saeland S, Duvert V, Poulet J, Gown AM et al. (1991) Granuloctye-macrophage colony-stimulating factor (GM-CSF) in human long-term bone marrow cultures: endogeneous production in the adherent layer and effect of exogeneous GM-CSF on granulomonopoiesis. Blood 78:1230–1236

    Google Scholar 

  • Deldar A, Lewis H, Bloom J, Weiss L (1988) Reproducible cloning assays for in vitro growth of canine hematopoietic progenitor cells and their potential applications in investigative hematotoxicity. Am J Vet Res 49:1393–1401

    Google Scholar 

  • Dessypris EN, Brenner DE, Hande KR (1986) Toxicity of doxorubicin metabolites to human erythroid and myeloid progenitors in vitro. Cancer Treat Rep 70:487–490

    Google Scholar 

  • Gaunt SD, Pierce KR (1986) Effects of estradiol on hematopoietic and marrow adherent cells of dogs. Am J Vet Res 47:906–909

    Google Scholar 

  • Gralla EJ, Fleischman RW, Luthra YK, Standnicki SW (1979) The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys. Toxicology 13:263–273

    Google Scholar 

  • Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66:1139–1143

    Google Scholar 

  • Klinnert V, Nothdurft W, Fliedner TM (1985) CFU-F from dog marrow: a colony assay and its significance. Blut 50:81–87

    Google Scholar 

  • Migliaccio AR, Migliaccio G, Johnson G, Adamson JW, Torok-Storb B (1990) Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients. Blood 75:305–312

    Google Scholar 

  • Myers CE, Mimnaugh EG, Yeh GC, Sinha BK (1988) Biochemical mechanisms of tumor cell kill by the anthracyclines. In: Lown JW (ed) Anthracycline and anthracenedione-based anti-cancer agents. Elsevier, New York, pp 527–569

    Google Scholar 

  • Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA et al. (1989a) Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 195:1580–1587

    Google Scholar 

  • Ogilvie GK, Richardson RC, Curtis CR, Withrow SJ, H. A. Reynolds V, Norris AM et al. (1989b) Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 195:1584–1587

    Google Scholar 

  • Ogilvie GK, Vail DM, Klein MK, Powers B, Dickinson K (1991) Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 198:1762–1764

    Google Scholar 

  • Postorino NC, Susaneck SJ, Withrow SJ, Macy DW, Harris C (1989) Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 25:221–225

    Google Scholar 

  • Smith DM, Kirk GR (1976) Some systemic effects of adriamycin on the dog. J Am Anim Hosp Assoc 12:92–97

    Google Scholar 

  • Spurling NW (1977) Haematology of the dog. In: Archer RK, Jeffcott LB (eds) Comparative clinical haematololgy. Blackwell Scientific Publications, Oxford, pp 365–440

    Google Scholar 

  • Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468

    Google Scholar 

  • Van Der Graaf WTA, De Vries EGE, Uges DRA, Nanninga AG, Meijer C, Vellenga et al. (1991) In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 48:616–622

    Google Scholar 

  • Wilson FD, Tavassoli M, Greenberg BR, Hinds D, Klein AK (1981) Morphological studies on ‘adherent cells’ in bone marrow cultures from humans, dogs, and mice. Stem Cells 1:15–29

    Google Scholar 

  • Young RC, Ozois RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139–153

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reagan, W.J., Handy, V., McKamey, A. et al. Effects of doxorubicin on the canine erythroid and myeloid progenitor cells and bone marrow microenvironment. Comp Haematol Int 3, 96–101 (1993). https://doi.org/10.1007/BF00368112

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00368112

Keywords

Navigation